We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals
LGND

357 hedge funds and large institutions have $4.15B invested in Ligand Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 133 increasing their positions, 115 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 43

22% more call options, than puts

Call options by funds: $8.48M | Put options by funds: $6.95M

16% more repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 115

7% more capital invested

Capital invested by funds: $3.89B → $4.15B (+$264M)

2% more funds holding

Funds holding: 349 → 357 (+8)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

0.18% less ownership

Funds ownership: 104.47% → 104.29% (-0.18%)

Holders
357
Holders Change
+8
Holders Change %
+2.29%
% of All Funds
4.39%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
59
Increased
133
Reduced
115
Closed
43
Calls
$8.48M
Puts
$6.95M
Net Calls
+$1.54M
Net Calls Change
-$3.42M

Top Buyers

1
Invesco
Invesco
Georgia
+$60.8M
2
NCGI
Next Century Growth Investors
Minnesota
+$19M
3
Bessemer Group
Bessemer Group
New Jersey
+$16.7M
4
Franklin Resources
Franklin Resources
California
+$15.2M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$12.9M

Top Sellers

1
UBS AM
UBS AM
Illinois
-$29.8M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$21M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$18.9M
4
NAMI
Nomura Asset Management International
Pennsylvania
-$14M
5
Goldman Sachs
Goldman Sachs
New York
-$9.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
WTC
326
WhitTier Trust Company
Nevada
$3.05K +$1.58K +8 +114%
FNWA
327
Financial Network Wealth Advisors
Utah
$2.79K – – –
WA
328
Westfuller Advisors
New York
$2.66K -$594 -3 -19%
EC
329
Elequin Capital
New York
$2.6K -$4.16K -21 -62%
FMII
330
Farmers & Merchants Investments Inc
Nebraska
$2.4K -$198 -1 -8%
PMAM
331
Picton Mahoney Asset Management
Ontario, Canada
$2.2K – – –
WA
332
WPG Advisers
Maryland
$2.2K – – –
RCM
333
Raleigh Capital Management
North Carolina
$2.2K +$2.18K +11 New
TM
334
Torren Management
California
$2K -$22.4K -113 -92%
CFD
335
Creative Financial Designs
Indiana
$2K – – –
PWMG
336
Private Wealth Management Group
New Jersey
$2K – – –
MCM
337
Manchester Capital Management
Vermont
$1.8K – – –
CFO
338
CVA Family Office
Colorado
$1.2K +$1.19K +6 New
AW
339
Avion Wealth
Texas
$1K – – –
AGWCA
340
Annis Gardner Whiting Capital Advisors
Florida
$799 – – –
PPC
341
Park Place Capital
Alabama
$799 – – –
FFO
342
Fortitude Family Office
Arizona
$799 +$594 +3 +300%
IAIM
343
International Assets Investment Management
Florida
$798 -$1.78K -9 -69%
AW
344
Ankerstar Wealth
Texas
$599 – – –
BTI
345
Blue Trust Inc
Georgia
$599 – – –
CA
346
CoreCap Advisors
Michigan
$599 – – –
JWA
347
JFS Wealth Advisors
Pennsylvania
$599 – – –
ZBNA
348
Zions Bancorporation, National Association
Utah
$599 – – –
GWM
349
Gilpin Wealth Management
Colorado
$599 +$198 +1 +50%
BIA
350
Bell Investment Advisors
California
$599 +$594 +3 New
12 13
14
15 16

LGND Hedge Fund Activity: Q1 2026 in Review

357 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2026, worth a combined $4.15B — up 6.8% from $3.89B a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new LGND positions and 43 closed out — a net gain of 16 holders — while 133 added to existing stakes and 115 trimmed.

The largest buyer was Invesco, adding an estimated $60.8M. The largest seller was UBS AM, cutting an estimated $29.8M.

  • 357 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2026, up from 349 in Q4 2025.
  • Funds reported $4.15B of Ligand Pharmaceuticals stock for Q1 2026, up 6.8% quarter-over-quarter.
  • 59 funds opened new Ligand Pharmaceuticals positions in Q1 2026 and 43 closed out, a net change of +16 holders.
  • The largest Ligand Pharmaceuticals buyer in Q1 2026 was Invesco, an estimated $60.8M added.
  • The largest Ligand Pharmaceuticals seller in Q1 2026 was UBS AM, an estimated $29.8M sold.

Based on aggregated 13F filings for Q1 2026.